41 results about "Thymosin beta-4" patented technology

Compositions and methods for treatment of skin utilizing thymosin β4.

The invention relates to recombinant thymosin Beta 4 two-repeat protein and a preparation method thereof. Human thymosin Beta 4 two-repeat gene expression vector pET-22b(+)-T Beta (2) is constructed through recombinant human thymosin Beta 4 full length cDNA combined with PCR technology, human thymosin Beta 4 that can not be expressed directly in colibacillus is highly actively expressed in colibacillus in the form of two-repeat and purified human thymosin Beta 4 two-repeat protein has biologic activity, can promote multiplication of lymphocyte of mice, has low immunogenicity and lays a foundation for the further research and wide application of human thymosin Beta 4.

The invention relates to recombinant thymosin Beta 4 two-repeat protein and a preparation method thereof. Human thymosin Beta 4 two-repeat gene expression vector pET-22b(+)-T Beta (2) is constructed through recombinant human thymosin Beta 4 full length cDNA combined with PCR technology, human thymosin Beta 4 that can not be expressed directly in colibacillus is highly actively expressed in colibacillus in the form of two-repeat and purified human thymosin Beta 4 two-repeat protein has biologic activity, can promote multiplication of lymphocyte of mice, has low immunogenicity and lays a foundation for the further research and wide application of human thymosin Beta 4.

A method of treating or preventing tissue damage occurring subsequent to affecting an increase in blood flow through a blood vessel which is in communication with the tissue, by administering an effective amount of a composition including a tissue damage-reducing or -preventing polypeptide including at least one of Thymosin beta 4 (TB4), an isoform of TB4, an N-terminal fragment of TB4, a C-terminal fragment of TB4, TB4 sulfoxide, an LKKTET [SEQ ID NO: 1] peptide, an LKKTNT [SEQ ID NO: 2] peptide, an actin-sequestering peptide, an actin binding peptide, an actin-mobilizing peptide, an actin polymerization-modulating peptide, or a conservative variant thereof having tissue damage-reducing activity. The composition is administered to the tissue before, during and / or after affecting the increase in blood flow.

The present invention relates to a therapeutic agent for ophthalmic disease containing thymosin beta 4. The present invention is more effective in reducing xerophthalmia than an ophthalmic solution containing cyclosporine A, is less irritant to eyes than conventional ophthalmic solutions and is physiochemically safe.

The invention relates to the field of disease treatment, in particular to a purpose of modified thymosin beta 4 for treating diabetic peripheral neuropathy in examinees (such as people), and a purposeof the thymosin beta 4 for preparing a medicine for treating the peripheral neuropathy in examinees (such as people). The invention further relates to a method for treating the peripheral neuropathy.The method comprises the step of applying the modified thymosin beta 4 to the examinee having the need.

The present invention provides embodiments which involve methods of providing a predetermined concentration of thymosin beta 4 (TB4) at a predetermined time, t, in a body portion of a live human patient. The methods can include determining a thymosin beta 4 treatment dosage (D) using Formula I: C=(A)D·t−B, wherein C is the predetermined concentration at time t, in ng / mL, D is the dosage of thymosin beta 4 administered in mg, t is the time elapsed after administration of dosage D in hours, A is about 30 to about 38, and B is about 0.5 to about 1; and administering the dosage (D) of thymosin beta 4 to the patient. Formula I may be, for example,C=(35.6)D·t−0.754  (Formula II).

The invention discloses a method for pyrolysis of thymosin beta-4. The method comprises the step of carrying out pyrolysis on thymosin beta-4 peptide resin to obtain crude peptide, wherein a mixed solvent of trifluoroacetic acid, thioanisole, dithioglycol, phenol, water, dimethyl sulfide and ammonium iodide is used as a pyrolysis reagent in the pyrolysis process. According to the method for pyrolysis of thymosin beta-4, the purity of crude peptide is greatly improved, meanwhile the total yield is greatly increased, the production cost is reduced, and the method is simple in process and convenient for industrial production.

The invention discloses a temperature-sensitive eye in-situ gel preparation suitable for phase inversion temperature. The temperature-sensitive eye in-situ gel preparation comprises different types ofpoloxamer 407 and 188. The in-situ gel preparation can be dosed in a liquid state under the condition of room temperature, and gel is formed on the surfaces of eyes. The stability of recombinant human thymosin beta 4 medicines can be enhanced, and the efficacy and the storage life of the medicines are prolonged.

A method of treatment for treating, at least partly preventing, inhibiting or reducing tissue deterioration, injury or damage due to a periodontal disease or disease of oral mucosa, or for restoring tissue adversely affected by the disease, in a subject, and / or for downregulating NF-kappaB or suppressing NF-kappaB mediated action in a body, organ, tissue or cell, includes administering to a subject, body, organ, tissue or cell an effective amount of a composition including a peptide agent including at least one of Thymosin beta 4 (Tβ4), an isoform of Tβ4, an N-terminal fragment of Tβ4, a C-terminal fragment of Tβ4, Tβ4 sulfoxide, an LKKTET peptide or conservative variant thereof, an LKKTNT peptide or conservative variant thereof, a KLKKTET peptide or conservative variant thereof, an LKKTETQ peptide or conservative variant thereof, Tβ4ala, Tβ9, Tβ10, Tβ11, Tβ12, Tβ13, Tβ14, Tβ15, gelsolin, vitamin D binding protein (DBP), profilin, cofilin, depactin, DnaseI, vilin, fragmin, severin, capping protein, β-actinin, acumentin, an actin-sequestering peptide, an actin binding peptide, an actin-mobilizing peptide, an actin polymerization-modulating peptide, or a stimulating agent that stimulates production of an effective amount of the peptide agent in the subject, body, organ, tissue or cell.

The invention belongs to the technical field of medical biology, and particularly relates to a preparation method for a human thymosin beta 4 two-string body protein. A target protein with purity more than 98% can be obtained through the preparation method, the obtained human thymosin beta 4 two-string body protein has biological activity, the activity of the protein is determined through proliferation experiments and migration experiments, and results show that the human thymosin beta 4 two-string body protein can promote proliferation and migration of cells and the activity of the human thymosin beta 4 two-string body protein is superior to that of a chemical synthesis monomer. The method only uses one chromatographic column to complete separation and purification of the target protein,is simple in steps, rapid and low in cost and lays a foundation for further study and wide application of human thymosin beta 4.

The invention discloses a recombined Tbeta 4-BP5 fusion peptide, a gene, an engineering bacteria and an application. The recombined fusion peptide is prepared by fusing thymosin beta 4 with Fabricius bursa pentapeptide BP5 through a soft Linker. The recombined Tbeta 4-BP5 fusion peptide gene is inserted into an expression vector to transfer the escherichia coli so as to obtain the gene engineering bacteria for effectively express the Tbeta 4-BP5 fusion peptide; the Tbeta 4-BP5 fusion peptide is prepared through liquid cultivation and purification; and the thioredoxin of the fusion peptide is eliminated by using enterokinase with His tag at the N-end, and the fusion peptide is further subjected to affinity chromatography purification so as to obtain the single recombined Tbeta 4-BP5 fusion peptide. The recombined Tbeta 4-BP5 fusion peptide disclosed by the invention can be used as a novel polypeptide immunologic adjuvant which is used in match with vaccines, can effectively enhance the organism cell immune level and the body liquid immune level, and has wide application prospects.

The invention relates to one section of thymosin beta 4 derivatives with high bioactivity which can be used to repair cornea, skin, and heart injury.

The invention discloses a temperature-sensitive ophthalmic in-situ gel preparation with a suitable phase transition temperature, which contains different types of poloxamers, and the preparation contains poloxamer 407 and poloxamer 188. The in situ gel can be administered in a liquid state at room temperature and forms a gel on the surface of the eye. The invention can enhance the stability of the recombinant human thymosin β4 drug and prolong the efficacy and shelf life of the drug.

The present invention relates to a therapeutic agent for ophthalmic disease containing thymosin beta 4. The present invention is more effective in reducing xerophthalmia than an ophthalmic solution containing cyclosporine A, is less irritant to eyes than conventional ophthalmic solutions and is physiochemically safe.